|1.||Yokomichi, Noriyuki: 1 article (03/2013)|
|2.||Yamaguchi, Yoko: 1 article (03/2013)|
|3.||Suzuki, Hiroyuki: 1 article (03/2013)|
|4.||Yoshioka, Ryosuke: 1 article (03/2013)|
|5.||Coler-Reilly, Ariella: 1 article (03/2013)|
|6.||Kubota, Yoshiki: 1 article (03/2013)|
|7.||Tozawa, Akiko: 1 article (03/2013)|
|8.||Suzuki, Nao: 1 article (03/2013)|
|9.||Nagasawa, Teruaki: 1 article (03/2013)|
|10.||Sun, Yang: 1 article (10/2012)|
10/01/2012 - "In the in vivo studies utilizing solid tumor-bearing rat, it was confirmed that PEGL-RA delivered remarkably larger amount of RA to tumor tissue and provided more significant anti-tumor activity than free RA. "
07/01/2008 - "In a human ovarian carcinoma mouse model, combination treatment with H-PEGL (0.4 mg/day for 30 days; intraperitoneal) and DDP (5 mg/kg on days 7, 11, 15, 19; intraperitoneal) acted synergistically to inhibit tumor growth by 91.48% without notable toxicity, but H-PEGL and DDP alone only inhibit tumor growth by 66.83% and 52.5% as compared to the NaCl solution control, respectively. "
01/01/2002 - "Previously we reported that encapsulation of tumor necrosis factor-alpha (TNF) in pegylated (STEALTH) liposomes (TNF-PEGL) dramatically improved circulation times of the protein and augmented accumulation in tumor tissue. "
|2.||Ovarian Neoplasms (Ovarian Cancer)
03/01/2013 - "PEGL-DOX is an excellent treatment for recurrent ovarian cancer that rarely causes side-effects like cardiotoxicity or hair loss, but frequently results in Hand-Foot Syndrome (HFS). "
07/01/2008 - "Our results showed us a splendid prospect of the clinical application of combination treatment on patients suffering from ovarian cancer with H-PEGL and DDP."
|3.||Weight Loss (Weight Reduction)
|4.||Sarcoma (Soft Tissue Sarcoma)
|1.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|6.||pegylated liposomal doxorubicin